DBV Technologies (NASDAQ:DBVT) Stock Price Expected to Rise, Citizens Jmp Analyst Says

Key Points

• Citizens Jmp raised its price target on DBV from $47 to $55 and kept a "market outperform" rating, implying about a 172.55% upside from the current share price.
• Analyst sentiment is mixed but tilted positive with a MarketBeat consensus of Moderate Buy and an average price target of $40.25 (ratings: 2 Strong Buy, 4 Buy, 1 Hold, 2 Sell).
• DBV traded at $20.18 and reported a quarterly EPS of ($0.55) vs. ($0.14) expected, reflecting deep negative margins and ROE, while institutional investors now own 71.74% after large stake increases by Artisan and Vivo.

DBV Technologies (NASDAQ:DBVT - Get Free Report) had its target price upped by Citizens Jmp from $47.00 to $55.00 in a report issued on Friday,Benzinga reports. The firm presently has a "market outperform" rating on the stock. Citizens Jmp's price target indicates a potential upside of 172.55% from the stock's current price.

Several other equities analysts have also issued reports on DBVT. Citigroup reiterated an "outperform" rating on shares of DBV Technologies in a research note on Friday. Guggenheim reiterated a "buy" rating and issued a $51.00 target price on shares of DBV Technologies in a research note on Friday, March 27th. Finally, Wall Street Zen lowered DBV Technologies from a "hold" rating to a "sell" rating in a research note on Saturday, March 28th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, DBV Technologies has a consensus rating of "Moderate Buy" and a consensus price target of $40.25.

DBV Technologies Stock Performance

DBVT traded down $0.82 on Friday, hitting $20.18. The company had a trading volume of 71,278 shares, compared to its average volume of 310,797. The stock has a fifty day moving average price of $20.89 and a 200-day moving average price of $18.85. DBV Technologies has a 12-month low of $7.53 and a 12-month high of $26.18. The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of -3.87 and a beta of -0.94.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.41). DBV Technologies had a negative net margin of 2,606.83% and a negative return on equity of 189.17%. The company had revenue of $0.90 million during the quarter, compared to analysts' expectations of $1.11 million. Analysts forecast that DBV Technologies will post -0.82 EPS for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

A number of large investors have recently modified their holdings of the business. Artisan Partners Limited Partnership grew its stake in shares of DBV Technologies by 6,273.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company's stock worth $63,435,000 after acquiring an additional 3,257,135 shares during the last quarter. Vivo Capital LLC grew its stake in shares of DBV Technologies by 133.4% during the fourth quarter. Vivo Capital LLC now owns 2,461,626 shares of the company's stock worth $47,189,000 after acquiring an additional 1,407,120 shares during the last quarter. Siren L.L.C. purchased a new stake in shares of DBV Technologies during the fourth quarter worth about $35,606,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of DBV Technologies during the second quarter worth about $9,659,000. Finally, MPM Bioimpact LLC purchased a new stake in shares of DBV Technologies during the second quarter worth about $9,649,000. Hedge funds and other institutional investors own 71.74% of the company's stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.